Patents by Inventor Nathalie Meurice

Nathalie Meurice has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Method of screening for a compound for inhibitory activity of FN14-tweak interaction
    Patent number: 9797882
    Abstract: The present disclosure is directed to methods of screening a compound for modulating activity at a TNF-like weak inducer of apoptosis (TWEAK) binding site on a cysteine-rich domain (CRD) of fibroblast growth factor-inducible 14 (Fn14). The present disclosure also provides heterocyclic compounds and pharmaceutically acceptable salts thereof and methods for the prevention, treatment, and amelioration of cell proliferative disorders with these compounds.
    Type: Grant
    Filed: July 9, 2014
    Date of Patent: October 24, 2017
    Assignee: The Translational Genomics Research Institute
    Inventors: Nhan Tran, Nathalie Meurice, Harshil Dhruv, Hongwei Yin
  • FN14 antagonists and therapeutic uses thereof
    Patent number: 9238034
    Abstract: The present disclosure is directed to methods of using fibroblast growth factor-inducible 14 (Fn14) antagonists to modulate activity at a TNF-like weak inducer of apoptosis (TWEAK) binding site on a cysteine-rich domain (CRD) of Fn14. The present disclosure also provides pharmaceutical compositions comprising synergistic combinations Fn14 antagonists and chemotherapeutic agents.
    Type: Grant
    Filed: July 9, 2014
    Date of Patent: January 19, 2016
    Assignee: THE TRANSLATIONAL GENOMICS RESEARCH INSTITUTE
    Inventors: Nhan Tran, Nathalie Meurice, Harshil Dhruv
  • FN14 ANTAGONISTS AND THERAPEUTIC USES THEREOF
    Publication number: 20150017263
    Abstract: The present disclosure is directed to methods of using fibroblast growth factor-inducible 14 (Fn14) antagonists to modulate activity at a TNF-like weak inducer of apoptosis (TWEAK) binding site on a cysteine-rich domain (CRD) of Fn14. The present disclosure also provides pharmaceutical compositions comprising synergistic combinations Fn14 antagonists and chemotherapeutic agents.
    Type: Application
    Filed: July 9, 2014
    Publication date: January 15, 2015
    Inventors: Nhan Tran, Nathalie Meurice, Harshil Dhruv